Member Info for Chazzy2

I think one of the issues here is that we're all comparing the share price to what it was a week/month/year/3 years ago and wondering why it's not steadily rising. The problem is the sp relates to market cap and net value which in FFWD's case you can't assign a value to because the normal metrics you would use to gauge value, i.e p/e, profit, revenue do not apply and we only have book value or purchase price to go on. If you assumed no progress has been made since the purchase of our investments then the sp would seem fair, but that is patently absurd as significance progress has clearly been made. But it's not being factored in.
It's a bit like assigning the value of a property to the cost price of all the materials used to make the house when the house is being built. The true value only comes through upon a sale. It's the same with FFWD. The true value will shine through upon the sale/IPO of the investee companies. Look how the sp went up on selling Nuuvera. And we don't just have houses to sell, we have mansions and grand estates! All in good time.

Cheers Pred. It is frustrating that there have been no more investments recently, as that always seems to inject a bit of positive sentiment in the company, but I suspect the board are holding back until the market settles down a bit. Probably not a bad strategy. I agree another cannabis investment could be good and certainly the sale of Nuuvera was hugely profitable for FFWD but I'm concerned that the cannabis market will eventually be dominated by the big players like Canopy, Aurora and Aphria, whose share prices are already very high and have factored in future growth, leaving the smaller players trodden underfoot. Also I feel the cannabis industry is very over-hyped at present. I personally would like to see a bigger stake in Juvenescence, as it has exposure to some of the most promising companies in AI medicine, which I believe is a very low key still in terms of public awareness but utterly transformative going forward as an industry.

It's been a real test of nerve for FFWD shareholders in recent weeks, and the frustrations are all to apparent from the posts and twitter messages recently. We appear to be in a bear market or at least a 'correction phase,' so things will not turn around much in the near term. The uncertainties of Brexit and global economic conditions generally are weighing down on markets. But the markets will recover, as they always do.
As far as FFWD is concerned, ignore the doom-mongerer posters who contribute nothing factually and who shouldn't be posting anyway if they have no interest in FFWD. Forget also the share price for a moment and look at the facts.
FFWD current market cap £16 m.
Our portfolio consists of amongst others:
(1) Leap Gaming which was nearly sold for £6m a year ago, before several tie-ups with major global games providers. Could now be worth £12 m??
(2) Yooya, the dark horse but currently in profit and generating well is excess of 2 billion views per month.
(3) Intensity, just posted very positive clinical trial results showing good safety and efficacy at low dosages. Could eventually be bought out for over a billion, worth at least £18m to FFWD.
(4) Juvenescence - plans to IPO next year. Currently worth $250 m so could IPO for $1 billion. FFWD stake would be worth $8 m.
(5) Factom - Enormous progress being made with series B fundraising ongoing and set to become leading global blockchain company in data security. Tim Draper predicting eventual market cap in excess of that IBM, Oracle and Palantir combined. Even if Factom achieves just 5% of the predicted future value FFWD stake could be worth $380 m.

FFWD has a diversified portfolio in some of the most promising technology areas of the future. Blockchain, cancer immunotherapy, longevity, video-gaming, student debt crisis etc.. Cash in the bank of about £4m following the placing, with more investments to come. My advice, hold and wait!

Very encouraging update from Intensity. It's still early days and the phase 1/2a trial won't complete until 2020 but at least we know that (1) the drug is safe in its IT delivery, (2) there is tumour shrinkage both at the local and distal tumour sites and (3) some evidence of immune activation. So all three boxes ticked in phase 1 alone which is quite remarkable. The exciting part starts now when they start increasing the dosage and eventually add immune activating components to the drug. Exciting times ahead for FFWD and SALV holders.

https://intensitytherapeutics.com/intensity-therapeutics-to-present-preliminary-data-from-clinical-study-of-int230-6-at-upcoming-medical-conferences/

Yooya are tweeting again. Must be all the bird feed.

https://www.youtube.com/watch?v=H1Ow9eLp8ZA

Listen from 10 min 30 secs onwards. This is the sound of a chairman of a company that is going places. The whole interview is worth listening too however.

Our ESMO poster presentation will be available on our website Saturday October 20th.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=FFWD&ArticleCode=vc9dhtw3&ArticleHeadline=Agreement

Anyone in any doubt as to Factom's progress should have another read of this. FFWD are hardly going to make their biggest investment so far unless they have total confidence. Factom cannot make announcements under NDA terms, but it doesn't mean that strong progress isn't being made.

I hope FFWD end up with a stake in Emmac as there aren't many plays in the medical cannabis space on the London market so it's a great opportunity and gives FFWD further diversification. We do need some updates soon though as patience is wearing thin. PR is definitely not their strong point.

Tweets from Intensity are coming in thick and fast now. I think the guys are really onto something.

So what's with the cryptic Nuuvera and Antonio Constanzo reference? Is someone implying that Emmac is on FFWD's shopping list. This is just speculation as there is no information to verify it, although there is the Ed Mcdermott link I suppose. I can see FFWD wanting to get back into the cannabis space after the Aphria success. Well time will tell.

Best to read the half-year report of the 27th Sept for the latest update. They're still waiting for approval from both Salv and Portage shareholders it would seem.

Yes exactly. Intensity's approach is quite different from other cancer drug approaches of the past. Intensity's management have long recognised that the traditional way of treating patents with chemotherapy i.e intravenously, has its limitations and delivers a low concentration of the drug to the tumour site, and with poor dispersion. So they're saying it's not the drug that's the problem, it's the way it's being delivered, and have found a way to deliver standard proven chemo drugs directly to the tumour, leaving healthy cells intact, whilst very importanly stimulating an immune response. So in a way it's a mixture of chemotherapy and immunotherapy.

Ed Mcdermott tweet:
"I really believe in Intensity’s management and their intratumoural drug. The team have already delivered a number of successful drugs and this could well be their biggest yet."

https://twitter.com/IntensityInc

Intensity is tweeting some interesting articles at the moment and quite regularly now. Looks like they could really be on to something. I hope FFWD take up the option to increase their stake. That would send out a very strong message about Intensity's progress.

I really hope Ffwd take up the options and invest further in Intensity. It will send a really strong signal that trial results to date are really promising. Well we only need to wait until the end of Sept to find out. Loads of other news could arrive from our other investments could arrive this month also. Very exciting times!

I'm inclined to agree that there will be a big sell off in Portage once the shares are transferred, as Salv investors take their profits, however in the medium term the Portage price will be determined initially by the outcome of Intensity Therapeutics, which will probably be the first of Portage's investees to return capital, all being well. If Intensity does reveal some trial results in the autumn, and those results are good, the Portage sp will seem low even without a sell off, givens Intensity's potential.

Nice gesture of Lorne's. He could have just donated cash to the charity but the fact that it's shares says as much about his confidence in the company as it does about his altruism.
Good on you Lorne.

"We believe the Warrant will be of interest to UK based institutional investors and the Company plans to present, with Intensity management, the results of the IT-01 study to date to interested parties over the Summer."

It's not clear from the above as to whether shareholders will be party to the above results to date or whether it will just be institutional investors. The phase 1/2a clinical trials are not due to complete until the end of 2020 so the information will be fairly limited at this stage. I guess a good gauge as to how well the trial is progressing will be whether FFWD take up the option to invest a further $5 m in Sept.

The sp is going to see-saw around because it is impossible to determine the NPV of all its investee companies. Only Vogogo is listed and so the market is assigning an arbitrary value based on 1. Net cash and 2. The book value of the investments. Until the investees are sold or IPO the guess work will continue.
Huge progress has been made with most of the investees and so the true value NPV should be higher than the market cap by now, but the market is pricing in the uncertainty factor until we see some hard figures.
Lorne has always said we need to be patient, and as long as the updates continue to be positive the sp is really immaterial at this stage even though it may seem frustrating at times.